Top Markets
Coin of the day
Radiopharm Theranostics Limited Radiopharm Theranostics Limited

Radiopharm Theranostics Limited

RAD
Classificação em ações #29698
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company,... Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Preço da ação
$0.00846342
Valor de mercado
$20.02M
Variação (1 dia)
0.00%
Variação (1 ano)
-47.56%
País
AU
Negociar Radiopharm Theranostics Limited (RAD)

Categoria

Histórico de preços das ações de Radiopharm Theranostics Limited (RAD)
Preço de fecho mais alto: $0.01 em 2026-08-01

Preço de fecho mais baixo: $0.24 em 2021-11-01
Histórico de preços das ações da Radiopharm Theranostics Limited de 2021 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) -22.82%
2025 -10.60%
2024 -63.52%
2023 -27.28%
2022 -71.97%
2021 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$527.89 35.09%
US
$996.61 51.72%
NL
$116.20 -20.17%
AU
$735.86 6.07%
CH
$257.75 14.92%
BE